Format

Send to

Choose Destination
Pancreas. 2016 Apr;45(4):541-5. doi: 10.1097/MPA.0000000000000539.

A Common CCK-B Receptor Intronic Variant in Pancreatic Adenocarcinoma in a Hungarian Cohort.

Author information

1
From the *First Department of Medicine, University of Szeged, Szeged, Hungary; †Department of Molecular and Cell Biology, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA; ‡Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Szeged, Hungary; §2nd Department of Pediatrics, Comenius University Medical School, University Children's Hospital, Bratislava, Slovakia; ∥First Department of Internal Medicine, University of Pécs, Hungary; ¶Institute of Surgery, University of Debrecen, Clinical Center, Debrecen, Hungary; #Heim Pál Children's Hospital, Budapest, Hungary; **First Department of Medicine, Szent György Teaching Hospital of County Fejér, Székesfehérvár, Hungary; ††Department of Oncotherapy, University of Szeged, Szeged, Hungary; and ‡‡MTA-SZTE Translational Gastroenterology Research Group, Szeged, Hungary.

Abstract

OBJECTIVES:

Variant c.811+32C>A in intron 4 of the cholecystokinin-B receptor gene (CCKBR) was reported to correlate with higher pancreatic cancer risk and poorer survival. The variant was suggested to induce retention of intron 4, resulting in a new splice form with enhanced receptor activity. Our objective was to validate the c.811+32C>A variant as an emerging biomarker for pancreatic cancer risk and prognosis.

METHODS:

We genotyped variant c.811+32C>A in 122 pancreatic adenocarcinoma case patients and 106 control subjects by sequencing and examined its association with cancer risk and patient survival. We tested the functional effect of variant c.811+32C>A on pre-messenger RNA splicing in human embryonic kidney 293T and Capan-1 cells transfected with CCKBR minigenes.

RESULTS:

The allele frequency of the variant was similar between patients and control subjects (18.4% and 17.9%, respectively). Survival analysis showed no significant difference between median survival of patients with the C/C genotype (266 days) and patients with the A/C or A/A genotypes (257 days). CCKBR minigenes with or without variant c.811+32C>A exhibited no difference in expression of the intron-retaining splice variant.

CONCLUSION:

These data indicate that variant c.811+32C>A in CCKBR does not have a significant impact on pancreatic cancer risk or survival in a Hungarian cohort.

PMID:
26646278
PMCID:
PMC4783207
DOI:
10.1097/MPA.0000000000000539
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center